US Patent Issued to Shanghai Escugen Biotechnology on Oct. 7 for "Human CD47-targeting single-domain antibody and use thereof" (Chinese Inventors)

ALEXANDRIA, Va., Oct. 8 -- United States Patent no. 12,435,135, issued on Oct. 7, was assigned to Shanghai Escugen Biotechnology Co. Ltd. (Shanghai).

"Human CD47-targeting single-domain antibody and use thereof" was invented by Xiangyu He (Shanghai), Weihong Nian (Shanghai), Chuanying Xu (Shanghai), Xintong Zheng (Shanghai), Xinmin Zhang (Shanghai), Jing Xiao (Shanghai), Feng He (Shanghai) and Qing Zhou (Shanghai).

According to the abstract* released by the U.S. Patent & Trademark Office: "The present application relates to an anti-CD47 single-domain antibody and a use thereof, and a method for preparing the antibody. The single-domain antibody comprises a CDR selected from the following CDRs: (1) CDR1, CDR2, and CDR3 shown by SEQ ID NO: ...